Therefore treatment strategies with beneficial effects toward reducing macrovascular complications (e.g., stroke, myocardial infarction) and with a low risk of adverse hypoglycemic events are being tested and although hypoglycemic events are reported in patients with heart failure [26], [27], GLP-1 analogues are considered agents with low risk of hypoglycaemia. The gene discussed is GLP1R; the disease is Stroke.